CN107050201A - The new application of Chinese patent drug Erding granules - Google Patents
The new application of Chinese patent drug Erding granules Download PDFInfo
- Publication number
- CN107050201A CN107050201A CN201710138478.4A CN201710138478A CN107050201A CN 107050201 A CN107050201 A CN 107050201A CN 201710138478 A CN201710138478 A CN 201710138478A CN 107050201 A CN107050201 A CN 107050201A
- Authority
- CN
- China
- Prior art keywords
- chinese patent
- chinese
- patent drug
- cell
- new application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A kind of new application of Chinese patent drug Erding granules, Erding granules are furuncle carbuncle poison, abscess of throat, the Chinese patent drug of wind-heat pinkeye caused by the burning hot poison of the treatment that Chinese violet, dandelion, Radix Isatidis, the mixed water decoction extract of Chinese lobelia plus auxiliary material are made is contained.Its new application is the pharmaceutical usage in treatment coronary arteriosclerosis.The positive effect of the present invention is：Indication scope is expanded for existing Chinese patent drug, is that the common disease for the treatment of cardiac and cerebral vascular diseases has augmented new drug, the Chinese medicine composition needs that different dosage forms can be prepared for patient, easy to carry, easily takes.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to the burning hot poison for the treatment of contains caused furuncle carbuncle poison, abscess of throat, wind
New application of the Chinese patent drug " Erding granules " of showing tremendous enthusiasm eye in terms of atherosclerosis is protected.
Background technology
Coronary atherosclerotic heart disease has turned into one of harm human health most important diseases, and its Etiological is
The formation of pulse atherosclerosis, atherosclerotic plaque it is unstable, last angiorrhoxis causes cardiocerebrovasculaevents events occur.It is dynamic
Pulse atherosclerosis are the diseases of class multi-pathogenesis interaction and generation, and the mechanism of atherogenesis is more complicated, high
Pionemia is the major reason that it occurs, in addition in the formation and development process Endothelial Cell of atherosclerosis
Damage also plays key effect.
In current integrative therapy, develop substantial amounts of medicine and clinically used, but to there is allergy anti-for Western medicine
Should, the adverse reaction such as digestive tract reaction, long-term taking toxic side effect substantially increases.In treatment clinical course, traditional Chinese medicine is got over
Favored to get over by patient, and contain borneol in some Chinese patent drugs, easy impairment of yang gas consumption, long-term use can make cardiac function on the contrary
Weaken.
Erding granules record Chinese Pharmacopoeia version 1 in 2015 at present, by Chinese violet, dandelion, Radix Isatidis, Chinese lobelia part
Composition function is with curing mainly to be clearing heat and detoxicating.Furuncle carbuncle poison, abscess of throat caused by being contained for burning hot poison, wind-heat pinkeye.As clear
Thermal detoxification class Chinese medicine, is mainly used in burning hot poison and contains caused furuncle carbuncle poison, abscess of throat, wind-heat pinkeye, heat-clearing class medicine is to dynamic
The protective effect traditional Chinese medical science of pulse atherosclerosis is just related to the discussion research of chest impediment and cardialgia heat toxin syndrome from ancient times, for example《Interior warp》In just
Have it is many cause pained record-heat and the obstruction of qi in the chest on heat evil, it is pained related；《The correction of the errors of medical works is pained》In also explicitly point out heat
Heresy can decoct cause silt etc..In recent years it has been proposed that " heat toxin " theory of pathogenesis on angiocardiopathy, and use method of dissipating heat and detoxifying
Treat disease of cardiovascular system." poison ", referring to has dysgenic material to body physiological function.It is malicious evil easily with pry-, phlegm, the stasis of blood,
Wet all heresies are cementing, especially poison it is evil most easily with fire-evil mutually and be disease, and the malicious stasis of blood more can be strongly fragrant and change fire, blood vessels of burning.These theories are
Heat-clearing and detoxifying drug provides theoretical foundation as a class medicine of protection atherosclerosis.
The content of the invention
Present invention aims at a kind of new application of Chinese patent drug Erding granules is provided, expand the indication model of existing patent medicine
Enclose, be that curative kind may be selected in common Atheromatosis increase.
The technical scheme is that：The burning hot poison for the treatment of contain caused by furuncle carbuncle poison, abscess of throat, in wind-heat pinkeye into
Medicine " Erding granules " is used for the pharmaceutical usage for treating coronary arteriosclerosis.
Usage and dosage：Boiling water is taken after mixing it with water.One time 1 bag, 3 times a day.It is within 1 month 1 course for the treatment of.
Confirmed through pharmacodynamic experiment, Erding granules have good effect for treating atherosclerosis, in being existing
Patent medicine expands indication scope, is that the common disease for the treatment of cardiac and cerebral vascular diseases has augmented new drug, and the Chinese medicine composition is needed for patient
Different dosage forms can be prepared, it is easy to carry, easily take.
Pharmacodynamics test.
1st, Experimental agents：Erding granules：It is 0.36g crude drugs to intend day dose, is taken day by 1 times, 2 times, 4 times of amount designs.
2nd, experiment material：Cell line Human umbilical vein endothelial cells HUVEC, is purchased from institute of oncology of Chinese Medical Sciences University, multiple
DEME high glucose mediums of the Su Houyong containing 20% hyclone is in 37 DEG C, 5%CO2Quiescent culture in saturated humidity incubator, 24h
Change liquid 1 time.(silent winged your the biochemistry product of generation of match is limited for DMEM high glucose mediums, hyclone, 0.25%EDTA trypsase
Company)；Dimethyl sulfoxide (DMSO) (Sigma companies)；MTT (Sigma companies)；Mycillin mixed liquor (the prosperous biological skill of Beijing ancient cooking vessel state
Art Co., Ltd).SOD, GSH-Px, NOS, NO detection kit build up Bioengineering Research Institute purchased from Nanjing.6- ketone-preceding
Row ring element (6-Keto-PGFl α) kit, nitric oxide (NO) kit, endothelin -1 (ET-1) kit are by Beijing North
Biotechnology research institute is provided.Soluble P-selection (PPS) plasminogen activator inhibitor (PAl-1) kit is by the Shanghai sun
Biotech company provides.
3rd, laboratory apparatus：SMP500-18272-LSIO ELIASAs：Manufactured in China Designed in
California USA；NIB-100F type inverted microscopes：Yongxin Optics Co Ltd, Ningbo；LD5-2A type low-speed centrifugals
Machine：Beijing Medical Centrifugal Machine Factory；HHS type electric-heated thermostatic water baths：Shanghai Medical Equipment Plant of Bo Xun Industrial Co., Ltd.s；
JA1103N type electronic balances：The limited public affairs of Shanghai Min Qiao precision scientific instruments：MCO-18AIC type CO2 incubators：SANYO GS；W-
CJ-1F type clean benches：Safe and sound company of Su Jing groups.
Specific implementation is as follows：
1st, to the protective effect of vascular endothelial cell
1.1 method HUVEC cell culture hyclones containing l0%, penicillin (1 × 105IU·L-1)/(streptomysin
100mg·L-1) DMEM high glucose mediums in 37 DEG C, 5%CO2Cultivated in saturated humidity incubator.Take the logarithm growth period cell,
Bottom of bottle cell is 1 × 10 up to single cell suspension, adjustment cell concentration is made when 80% of 0.25% Trypsin Induced5Individual ml-1, it is inoculated in 96 orifice plates, per the μ l of hole 200, made a circle in 96 orifice plate weeks only plus nutrient solution is not added with cell to prevent edge effect, point
Group experiment.
1.1.1 cell packet and MTT detection HUVEC cells press 1 × 105Individual/hole is inoculated in 96 orifice plates, and culture 24h is adherent
Cell is randomly divided into 5 groups afterwards：Normal group, H2O2Model group, Erding granules (12.5mgL-1), in (25mgL-1)、
Height (50mgL-1) dosage group；First respectively with containing 12.5,25,50mgL-1Concentration Chinese medicine composition culture medium preculture
24h.Control group and model group are replaced after preculture same time with culture medium, remove original fluid, with PBS 2 times.Except just
Remaining each group cell of normal control group is changed containing 400 μm of oL-1H2O2Culture medium stimulates 12h, removes culture medium after termination, addition contains
There is 0.5gL-1MTT serum free mediums, are incubated after 4h, abandon supernatant, add 150 μ l dimethyl sulfoxide (DMSO)s, vibration mix after
Absorbance under 492nm wavelength is determined on ELIASA, cell viability is calculated.
1.1.2 NO assays in nutrient solution
Cell is pressed after " 1.1 " method packet transaction, collects supernatant, and the method described according to kit specification is determined
NO contents in each group cell conditioned medium, all experiments are at least repeated 3 times.
1.1.3 SOD, GSH-Px, NOS determination of activity in cell pyrolysis liquid
Cell is pressed after " 1.1 " method packet transaction, uses 0.25% trypsin digestion and cell, PBS is washed 2 times, by cell
RIPA lysates are suspended in, 30min, 4 DEG C, 14000rmin are placed on ice-110min is centrifuged, cell pyrolysis liquid is collected, according to
Method described in kit specification, determines OD, GSH-Px, NOS activity.
2nd, to the protective effect of experimental atherosclerosis blood vessel endothelium injury
2.1 method：Healthy Male New Zealand rabbits 30, body weight 2.0-2.5kg at monthly age 3-4 month, is randomly divided into 5 groups：Just
Chang Zuyong normal diets are fed, while in experiment the 13rd week to 16 weekends, physiological saline 10mlkg-1Gavage；The high fat of model group
Forage feed, high lipid food is that 1% cholesterol, 5% lard are added in normal diet, while in experiment the 13rd week to 16 weeks
End, physiological saline 10mlkg-1Gavage；Chinese medicine composition low dosage (5.6gkg-1) the group same model group of feed, while in reality
The 13rd week is tested to 16 weekends, 10mlkg-1Gavage；Chinese medicine composition high dose group (11.2gkg-1) the same model group of feed, together
When in experiment the 13rd week to 16 weekends, 10mlkg-1Gavage；The same model group of positive controls feed, while in experiment the 13rd week
To 16 weekends, atorvastatin calcium (0.9mgkg-1), 10mlkg-1Gavage.
The separation of 2.2 16 weekend Anaesthetic Rabbits surveys serum and determines TC, TG, HDL-C, LDL-C, PPS, NO, sodium citrate anti-freezing
Separated plasma, ELISA determines ET-1,6-Keto-PGFl α.Air embolism puts to death animal, and thoracic cavity and abdominal cavity are opened immediately,
Sustainer is taken out, sample is soaked with 10% formalin solution to be fixed,
Conventional materials, FFPE, section, HE dyeing, optical microphotograph Microscopic observation Pathologic changes.
3rd, experimental result
3.1 the protective effect to vascular endothelial cell
As a result H is shown2O2After damaging cells, model control group cell absorbance is substantially reduced, and cell viability also substantially drops
It is low, show that cell sustains damage, and the middle and high dosage group absorbance of Chinese medicine composition is dramatically increased, cell viability is increased to
70% or so the, (p that compared that there were significant differences with model control group<0.05, p<0.01), it is shown in Table 1.
Influence of the table 1 to blood vessel HUVEC cells absorbance and cell viability
Compared * p with model control group<0.05, * * p<0.01
The influence of NO and intracellular SOD, GSH-Px, NOS activity in 3.2 pairs of HUVEC cell liquid
As a result show, the intracellular SOD vigor of model group is substantially reduced, GSH-Px and NOS contents are substantially reduced, cell culture
NO contents also decline in liquid.The middle and high dosage group of Chinese medicine composition can significantly improve intracellular SOD vigor, increase GSH-Px and
NO contents in NOS contents, rise the cell liquid, (p that compared that there were significant differences with model group<0.05, p<0.01) 2, be the results are shown in Table
Influence of the table 2 to NO in HUVEC cell liquid and intracellular SOD, GSH-Px, NOS activity
Compared * p with model control group<0.05, * * p<0.01
The influence of 3.3 pairs of Experimental Atherosclerotic Rabbits blood lipids index
As a result show, TC in positive control and the suppression serum that Chinese medicine composition is low, high dose group can be different degrees of,
TG, LDL-C content are raised, and promote the release of HDL-C contents, have protection adjustment effect to blood fat, being compared with model control group has
Significant difference (p<0.05, * * p<0.01, * * * p<0.01) 3, be the results are shown in Table.
Table 3 to TC, TG, LDL-C, HDL-C content in serum influence (N=6)
Compared * p with model control group<0.05, * * p<0.01, * * * p<0.01
3.4 couples of plasma in rabbit PPS, ET-1,6-Keto-PGFl α and serum NO levels influence
As a result show, positive controls and Chinese medicine composition is low, high dose group can substantially suppress PPS, ET-1 in blood plasma
And serum NO release, promote the release of 6-Keto-PGFl alpha contents, have certain adjustment effect to coagulation factor, with model comparison
Group compares that there were significant differences (p<0.05, * * p<0.01, * * * p<0.01) 4, be the results are shown in Table.
Table 4 to PPS, ET-1, NO, 6-Keto-PGFl alpha content in serum influence (N=6)
Compared * p with model control group<0.05, * * p<0.01, * * * p<0.01
3.5 pathomorphology change
3.5.1 visually observe
Blank group active vessel lumen is smooth complete.Model group forms vertical at the jag of aortic root and branching blood vessels
Capable wire focus and the Lipid Plaque of lark, surface are smooth.In positive controls and the whole sustainer of Chinese medicine composition group
Film is in lark or canescence muddy appearance, has the pinhead-sized punctate lesion of cap, its pathological change subtracts compared with model group
Gently.
3.5.2 observation by light microscope
Naive animals endangium no abnormality seen.Model group arterial lumen substantially narrow it is rough and uneven in surface, endothelial cell increase
Raw swelling, interior elastic membrane is interrupted or disappears, and subendothelial layer gap is significantly increased, it is seen that a large amount of lipidosis, foam cells, lymph
Cell, plasmocyte infiltrating；Middle film shallow structure is disorderly, and muscle fibre separation, elastic plate is disorderly, smooth muscle cell enlargement hyperplasia, to
Tube chamber side is migrated.Positive controls and Chinese medicine composition is low, high dose group animal blood vessels inner membrance has slight Focal hyperplasia, endothelium
Hyperplasia, subendothelial layer slightly increases, has a small amount of cured matter deposition：Middle film shallow structure is varied slightly, compared with model group
Mitigate compared with its pathological change.
Conclusion：
1st, Erding granules can improve the HUVEC cell survival rates of oxidative stress status, and can improve intracellular SOD
With GSH-Px, NOS activity, increase NO levels in culture medium, illustrate that Erding granules can raise Cellular Oxidation system of defense
Activity, removes free radical, promotes endogenous NO generation and discharges, and is to hinder dynamic so as to protect cells from oxidativestress damage
The key link of pulse atherosclerosis early stage morbidity.
2nd, Erding granules have the endocrine dysfunction of protection blood vessel endothelium, adjust antiotasis, suppress that blood is small pulls work
Change and local inflammation reaction, adjust fibrinolytic system to improve function of vascular endothelium, and then prevent the progress of atherosclerosis.
3rd, Erding granules can effectively reduce TC, TG, LDL-C content in serum, improve HDL-C contents, have to blood fat
Obvious adjustment effect, reduces the deposition of lipid in the tissue, and then can mitigate the inflammatory reaction of serum and plaque,
Reduce lining endothelium knuckle patch to be formed, play study of anti-atherogenic effect.
In summary, there is Erding granules significant antiatherosclerotic reason to act on, in clinical cardiovascular and cerebrovascular disease
Prophylactic treatment in have application prospect.
Claims (1)
1. the new application of Chinese patent drug Erding granules, it is characterized in that：The burning hot poison for the treatment of contains caused furuncle carbuncle poison, abscess of throat, wind
The Chinese patent drug Erding granules of showing tremendous enthusiasm eye are used for the pharmaceutical usage for treating coronary arteriosclerosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710138478.4A CN107050201A (en) | 2017-03-09 | 2017-03-09 | The new application of Chinese patent drug Erding granules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710138478.4A CN107050201A (en) | 2017-03-09 | 2017-03-09 | The new application of Chinese patent drug Erding granules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107050201A true CN107050201A (en) | 2017-08-18 |
Family
ID=59622512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710138478.4A Withdrawn CN107050201A (en) | 2017-03-09 | 2017-03-09 | The new application of Chinese patent drug Erding granules |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107050201A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108478734A (en) * | 2018-05-04 | 2018-09-04 | 钟成林 | A kind of Tea containing traditional Chinese medicine for treating hypertension and condensed blood lipid |
| CN112891438A (en) * | 2021-03-16 | 2021-06-04 | 宁夏医科大学 | Traditional Chinese medicine composition for preventing and treating atherosclerosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784245A (en) * | 2012-08-01 | 2012-11-21 | 李虹霖 | Erding granule and preparation method thereof |
| CN105343350A (en) * | 2015-11-24 | 2016-02-24 | 江西本草天工科技有限责任公司 | Application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases |
-
2017
- 2017-03-09 CN CN201710138478.4A patent/CN107050201A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784245A (en) * | 2012-08-01 | 2012-11-21 | 李虹霖 | Erding granule and preparation method thereof |
| CN105343350A (en) * | 2015-11-24 | 2016-02-24 | 江西本草天工科技有限责任公司 | Application of Erding granules in preparation of drugs for treating or preventing hyperuricemia and gout diseases |
Non-Patent Citations (3)
| Title |
|---|
| 范秀珍等: "清热解毒类中药抗动脉粥样硬化作用机制的研究进展", 《中国动脉硬化杂志》 * |
| 贾红慧等: "二丁颗粒的抑菌抗炎和免疫调节作用", 《华西药学杂志》 * |
| 赵钢等: "化瘀祛痰法干预对动脉硬化家兔血清P 选择素及PAI - 1 水平的影响", 《辽宁中医杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108478734A (en) * | 2018-05-04 | 2018-09-04 | 钟成林 | A kind of Tea containing traditional Chinese medicine for treating hypertension and condensed blood lipid |
| CN112891438A (en) * | 2021-03-16 | 2021-06-04 | 宁夏医科大学 | Traditional Chinese medicine composition for preventing and treating atherosclerosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shu-Hua | Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins | |
| CN102114044B (en) | Artificially processed bear bile powder and preparation method thereof | |
| Pitchaipillai et al. | In vitro antidiabetic activity of ethanolic leaf extract of bruguiera Cylindrica L.–glucose uptake by yeast cells method | |
| CN109846896A (en) | Hederagenin is preparing the application in anti-vascular endothelial cell inflammatory damage drug | |
| Lu et al. | Advances in the therapeutic application and pharmacological properties of kinsenoside against inflammation and oxidative stress-induced disorders | |
| CN107050201A (en) | The new application of Chinese patent drug Erding granules | |
| CN106519054A (en) | Radix pseudostellariae homogeneous polysaccharide for promoting insulin secretion of islet cells and use thereof | |
| Han et al. | [Retracted] Immunomodulatory Effect of Lycium barbarum Polysaccharides against Liver Fibrosis Based on the Intelligent Medical Internet of Things | |
| CN104667175B (en) | A kind of health products with protection alcoholic liver injury function | |
| CN104873560B (en) | A kind of setose thistle general flavone and preparation method thereof with preparing the application in antitumor or liver-protecting medicine | |
| CN103655929B (en) | Pharmaceutical composition with liver-protecting effect and preparation method thereof | |
| KR20150014033A (en) | Food composition for liver activity contaning Water extract of Cordyceps militaris and its manufacturing method | |
| Choda | Medicinal value of Cordyceps sinensis | |
| CN109045035A (en) | Application of 7- (2,2- dimethyl -3- crotonoyl the amido)-octahydro benzene quinoline acetic acid esters in preparation treatment liver disease drug | |
| CN104906162A (en) | Preparing method and application of rhizoma atractylodis volatile oil | |
| Liu et al. | Fermented Gynochthodes officinalis (FC How) Razafim. & B. Bremer alleviates diabetic erectile dysfunction by attenuating oxidative stress and regulating PI3K/Akt/eNOS pathway | |
| CN101168008B (en) | Medicinal composition with tumor inhibition function and preparation method and application thereof | |
| CN112022892B (en) | Application of organic extract of plant of Cirsium | |
| CN109395015B (en) | Application of rheumatism and pain relieving traditional Chinese medicine composition in preparation of anti-angiogenesis medicine | |
| CN112007058A (en) | Application of oroxylum indicum as antioxidant stress injury agent | |
| CN106539979A (en) | A kind of Chinese medicine preparation for treating allergic rhinitises | |
| CN106890189A (en) | Application of the chonglou saponin in antineoplastic sensitizer is prepared | |
| Yang et al. | Hypoglycemic Action of Polyphenols from Toona Sinensis. | |
| CN101112417A (en) | Rheum defervescence liniment and method for preparing the same | |
| Sharmila et al. | Anti-diabetic potential of Indian medicinal plants with Garcinia kola and Syzygium cumini |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170818 |